Pharmacological options for the treatment of chronic migraine pain
Copyright © 2020. Published by Elsevier Ltd..
Migraine is a debilitating neurological condition with symptoms typically consisting of unilateral and pulsating headache, sensitivity to sensory stimuli, nausea, and vomiting. The World Health Organization (WHO) reports that migraine is the third most prevalent medical disorder and second most disabling neurological condition in the world. There are several options for preventive migraine treatments that include, but are not limited to, anticonvulsants, antidepressants, beta blockers, calcium channel blockers, botulinum toxins, NSAIDs, riboflavin, and magnesium. Patients may also benefit from adjunct nonpharmacological options in the comprehensive prevention of migraines, such as cognitive behavior therapy, relaxation therapies, biofeedback, lifestyle guidance, and education. Preventative therapies are an essential component of the overall approach to the pharmacological treatment of migraine. Comparative studies of newer therapies are needed to help patients receive the best treatment option for chronic migraine pain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical anaesthesiology - 34(2020), 3 vom: 06. Sept., Seite 383-407 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Urits, Ivan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 01.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bpa.2020.08.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315745606 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315745606 | ||
| 003 | DE-627 | ||
| 005 | 20231225155600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bpa.2020.08.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315745606 | ||
| 035 | |a (NLM)33004155 | ||
| 035 | |a (PII)S1521-6896(20)30069-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological options for the treatment of chronic migraine pain |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 01.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
| 520 | |a Migraine is a debilitating neurological condition with symptoms typically consisting of unilateral and pulsating headache, sensitivity to sensory stimuli, nausea, and vomiting. The World Health Organization (WHO) reports that migraine is the third most prevalent medical disorder and second most disabling neurological condition in the world. There are several options for preventive migraine treatments that include, but are not limited to, anticonvulsants, antidepressants, beta blockers, calcium channel blockers, botulinum toxins, NSAIDs, riboflavin, and magnesium. Patients may also benefit from adjunct nonpharmacological options in the comprehensive prevention of migraines, such as cognitive behavior therapy, relaxation therapies, biofeedback, lifestyle guidance, and education. Preventative therapies are an essential component of the overall approach to the pharmacological treatment of migraine. Comparative studies of newer therapies are needed to help patients receive the best treatment option for chronic migraine pain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a migraine | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a preventive therapy | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 650 | 7 | |a Histamine Antagonists |2 NLM | |
| 700 | 1 | |a Gress, Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Charipova, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Zamarripa, Alec M |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Parth M |e verfasserin |4 aut | |
| 700 | 1 | |a Lassiter, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Jai Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical anaesthesiology |d 2002 |g 34(2020), 3 vom: 06. Sept., Seite 383-407 |w (DE-627)NLM122752538 |x 1878-1608 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:3 |g day:06 |g month:09 |g pages:383-407 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bpa.2020.08.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 3 |b 06 |c 09 |h 383-407 | ||